These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33432682)

  • 1. Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.
    d'Ancona G; Kavanagh JE; Dhariwal J; Hearn AP; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Jackson DJ; Kent BD
    Allergy; 2021 Jul; 76(7):2238-2241. PubMed ID: 33432682
    [No Abstract]   [Full Text] [Related]  

  • 2. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benralizumab: an updated treatment of eosinophilic asthma.
    Cushen B; Menzies-Gow A
    Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
    [No Abstract]   [Full Text] [Related]  

  • 4. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 6. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
    Albers FC; Price RG; Smith SG; Yancey SW
    J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231
    [No Abstract]   [Full Text] [Related]  

  • 7. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benralizumab: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):505-511. PubMed ID: 29464664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reslizumab as add-on therapy in patients with refractory asthma.
    Virchow JC; McDonald M; Garin M; Korn S
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32273395
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
    Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
    Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
    [No Abstract]   [Full Text] [Related]  

  • 13. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 16. Mepolizumab use: Post-approval academic practice experience.
    Benjamin MR; Bochner BS; Peters AT
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
    [No Abstract]   [Full Text] [Related]  

  • 17. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Castro M; Bacharier LB
    Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
    [No Abstract]   [Full Text] [Related]  

  • 20. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.